Biology:NF-κB

From HandWiki
Short description: Nuclear transcriptional activator that binds to enhancer elements in many different cell types
Mechanism of NF-κB action. The classic "canonical" NF-κB complex is a heterodimer of p50 and RelA,[1] as shown. NF-κB waits for activation in the cytosol, complexed with the inhibitory protein IκBα. Various extracellular signals can enter the cell via membrane receptors and activate the enzyme IκB kinase (IKK). IKK, in turn, phosphorylates the IκBα protein, which results in ubiquitination, dissociation of IκBα from NF-κB, and eventual degradation of IκBα by the proteasome. The activated NF-κB is then translocated into the nucleus where it binds to specific sequences of DNA called response elements (RE). The DNA/NF-κB complex then recruits other proteins such as coactivators and RNA polymerase, which transcribe downstream DNA into mRNA. In turn, mRNA is translated into protein, resulting in a change of cell function.[2][3][4][5]

Nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) is a family of transcription factor protein complexes that controls transcription of DNA, cytokine production and cell survival. NF-κB is found in almost all animal cell types and is involved in cellular responses to stimuli such as stress, cytokines, free radicals, heavy metals, ultraviolet irradiation, oxidized LDL, and bacterial or viral antigens.[2][3][4][6][7] NF-κB plays a key role in regulating the immune response to infection. Incorrect regulation of NF-κB has been linked to cancer, inflammatory and autoimmune diseases, septic shock, viral infection, and improper immune development. NF-κB has also been implicated in processes of synaptic plasticity and memory.[8][9][10][11][12][13]

Discovery

NF-κB was discovered by Ranjan Sen in the lab of Nobel laureate David Baltimore via its interaction with an 11-base pair sequence in the immunoglobulin light-chain enhancer in B cells.[14] Later work by Alexander Poltorak and Bruno Lemaitre in mice and Drosophila fruit flies established Toll-like receptors as universally conserved activators of NF-κB signalling. These works ultimately contributed to awarding of Nobel laureates to Bruce Beutler and Jules A. Hoffmann, who were the principal investigators of those studies.[15][16][17]

Structure

All proteins of the NF-κB family share a Rel homology domain in their N-terminus. A subfamily of NF-κB proteins, including RelA, RelB, and c-Rel, have a transactivation domain in their C-termini. In contrast, the NF-κB1 and NF-κB2 proteins are synthesized as large precursors, p105 and p100, which undergo processing to generate the mature p50 and p52 subunits, respectively. The processing of p105 and p100 is mediated by the ubiquitin/proteasome pathway and involves selective degradation of their C-terminal region containing ankyrin repeats. Whereas the generation of p52 from p100 is a tightly regulated process, p50 is produced from constitutive processing of p105.[18][19] The p50 and p52 proteins have no intrinsic ability to activate transcription and thus have been proposed to act as transcriptional repressors when binding κB elements as homodimers.[20][21] Indeed, this confounds the interpretation of p105-knockout studies, where the genetic manipulation is removing an IκB (full-length p105) and a likely repressor (p50 homodimers) in addition to a transcriptional activator (the RelA-p50 heterodimer).

Members

NF-κB family members share structural homology with the retroviral oncoprotein v-Rel, resulting in their classification as NF-κB/Rel proteins.[2]

There are five proteins in the mammalian NF-κB family:[22]

Class Protein Aliases Gene
I NF-κB1 p105 → p50 NFKB1
NF-κB2 p100 → p52 NFKB2
II RelA p65 RELA
RelB RELB
c-Rel REL

The NF-κB/Rel proteins can be divided into two classes, which share general structural features:[1]

Schematic diagram of NF-κB protein structure.[1] There are two structural classes of NF-κB proteins: class I (top) and class II (bottom). Both classes of proteins contain a N-terminal DNA-binding domain (DBD), which also serves as a dimerization interface to other NF-κB transcription factors and, in addition, binds to the inhibitory IκBα protein. The C-terminus of class I proteins contains a number of ankyrin repeats and has transrepression activity. In contrast, the C-terminus of class II proteins has a transactivation function.[2][3][4][5]

Below are the five human NF-κB family members:

NFKB1
1SVC.png
Top view of the crystallographic structure (PDB: 1SVC​) of a homodimer of the NFKB1 protein (green and magenta) bound to DNA (brown).
Identifiers
SymbolNFKB1
NCBI gene4790
HGNC7794
OMIM164011
RefSeqNM_003998
UniProtP19838
Other data
LocusChr. 4 q24
RELA
2RAM.png
Side view of the crystallographic structure (PDB: 2RAM​) of a homodimer of the RELA protein (green and magenta) bound to DNA (brown).
Identifiers
SymbolRELA
NCBI gene5970
HGNC9955
OMIM164014
RefSeqNM_021975
UniProtQ04206
Other data
LocusChr. 11 q13
NFKB2
Identifiers
SymbolNFKB2
NCBI gene4791
HGNC7795
OMIM164012
RefSeqNM_002502
UniProtQ00653
Other data
LocusChr. 10 q24
RELB
Identifiers
SymbolRELB
NCBI gene5971
HGNC9956
OMIM604758
RefSeqNM_006509
UniProtQ01201
Other data
LocusChr. 19 q13.2-19q13
REL
Identifiers
SymbolREL
NCBI gene5966
HGNC9954
OMIM164910
RefSeqNM_002908
UniProtQ04864
Other data
LocusChr. 2 p13-p12

Species distribution and evolution

In addition to mammals, NF-κB is found in a number of simple animals as well.[23] These include cnidarians (such as sea anemones, coral and hydra), porifera (sponges), single-celled eukaryotes including Capsaspora owczarzaki and choanoflagellates, and insects (such as moths, mosquitoes and fruitflies). The sequencing of the genomes of the mosquitoes A. aegypti and A. gambiae, and the fruitfly D. melanogaster has allowed comparative genetic and evolutionary studies on NF-κB. In those insect species, activation of NF-κB is triggered by the Toll pathway (which evolved independently in insects and mammals) and by the Imd (immune deficiency) pathway.[24]

Signaling

Effect of activation

NF-κB (green) heterodimerizes with RelB (cyan) to form a ternary complex with DNA (orange) that promotes gene transcription.[25]

NF-κB is crucial in regulating cellular responses because it belongs to the category of "rapid-acting" primary transcription factors, i.e., transcription factors that are present in cells in an inactive state and do not require new protein synthesis in order to become activated (other members of this family include transcription factors such as c-Jun, STATs, and nuclear hormone receptors). This allows NF-κB to be a first responder to harmful cellular stimuli. Known inducers of NF-κB activity are highly variable and include reactive oxygen species (ROS), tumor necrosis factor alpha (TNFα), interleukin 1-beta (IL-1β), bacterial lipopolysaccharides (LPS), isoproterenol, cocaine, endothelin-1 and ionizing radiation.[26]

NF-κB suppression of tumor necrosis factor cytotoxicity (apoptosis) is due to induction of antioxidant enzymes and sustained suppression of c-Jun N-terminal kinases (JNKs).[27]

Receptor activator of NF-κB (RANK), which is a type of TNFR, is a central activator of NF-κB. Osteoprotegerin (OPG), which is a decoy receptor homolog for RANK ligand (RANKL), inhibits RANK by binding to RANKL, and, thus, osteoprotegerin is tightly involved in regulating NF-κB activation.[28]

Many bacterial products and stimulation of a wide variety of cell-surface receptors lead to NF-κB activation and fairly rapid changes in gene expression.[2] The identification of Toll-like receptors (TLRs) as specific pattern recognition molecules and the finding that stimulation of TLRs leads to activation of NF-κB improved our understanding of how different pathogens activate NF-κB. For example, studies have identified TLR4 as the receptor for the LPS component of Gram-negative bacteria.[29] TLRs are key regulators of both innate and adaptive immune responses.[30]

Unlike RelA, RelB, and c-Rel, the p50 and p52 NF-κB subunits do not contain transactivation domains in their C terminal halves. Nevertheless, the p50 and p52 NF-κB members play critical roles in modulating the specificity of NF-κB function. Although homodimers of p50 and p52 are, in general, repressors of κB site transcription, both p50 and p52 participate in target gene transactivation by forming heterodimers with RelA, RelB, or c-Rel.[31] In addition, p50 and p52 homodimers also bind to the nuclear protein Bcl-3, and such complexes can function as transcriptional activators.[32][33][34]

Inhibition

In unstimulated cells, the NF-κB dimers are sequestered in the cytoplasm by a family of inhibitors, called IκBs (Inhibitor of κB), which are proteins that contain multiple copies of a sequence called ankyrin repeats. By virtue of their ankyrin repeat domains, the IκB proteins mask the nuclear localization signals (NLS) of NF-κB proteins and keep them sequestered in an inactive state in the cytoplasm.[35]

IκBs are a family of related proteins that have an N-terminal regulatory domain, followed by six or more ankyrin repeats and a PEST domain near their C terminus. Although the IκB family consists of IκBα, IκBβ, IκBε, and Bcl-3, the best-studied and major IκB protein is IκBα. Due to the presence of ankyrin repeats in their C-terminal halves, p105 and p100 also function as IκB proteins. The c-terminal half of p100, that is often referred to as IκBδ, also functions as an inhibitor.[36][37] IκBδ degradation in response to developmental stimuli, such as those transduced through LTβR, potentiate NF-κB dimer activation in a NIK dependent non-canonical pathway.[36][38]

Activation process (canonical/classical)

Activation of the NF-κB is initiated by the signal-induced degradation of IκB proteins. This occurs primarily via activation of a kinase called the IκB kinase (IKK). IKK is composed of a heterodimer of the catalytic IKKα and IKKβ subunits and a "master" regulatory protein termed NEMO (NF-κB essential modulator) or IKKγ. When activated by signals, usually coming from the outside of the cell, the IκB kinase phosphorylates two serine residues located in an IκB regulatory domain. When phosphorylated on these serines (e.g., serines 32 and 36 in human IκBα), the IκB proteins are modified by a process called ubiquitination, which then leads them to be degraded by a cell structure called the proteasome.

With the degradation of IκB, the NF-κB complex is then freed to enter the nucleus where it can 'turn on' the expression of specific genes that have DNA-binding sites for NF-κB nearby. The activation of these genes by NF-κB then leads to the given physiological response, for example, an inflammatory or immune response, a cell survival response, or cellular proliferation. Translocation of NF-κB to nucleus can be detected immunocytochemically and measured by laser scanning cytometry.[39] NF-κB turns on expression of its own repressor, IκBα. The newly synthesized IκBα then re-inhibits NF-κB and, thus, forms an auto feedback loop, which results in oscillating levels of NF-κB activity.[40] In addition, several viruses, including the AIDS virus HIV, have binding sites for NF-κB that controls the expression of viral genes, which in turn contribute to viral replication or viral pathogenicity. In the case of HIV-1, activation of NF-κB may, at least in part, be involved in activation of the virus from a latent, inactive state.[41] YopP is a factor secreted by Yersinia pestis, the causative agent of plague, that prevents the ubiquitination of IκB. This causes this pathogen to effectively inhibit the NF-κB pathway and thus block the immune response of a human infected with Yersinia.[42]

Inhibitors of NF-κB activity

Concerning known protein inhibitors of NF-κB activity, one of them is IFRD1, which represses the activity of NF-κB p65 by enhancing the HDAC-mediated deacetylation of the p65 subunit at lysine 310, by favoring the recruitment of HDAC3 to p65. In fact IFRD1 forms trimolecular complexes with p65 and HDAC3.[43][44]

The NAD+-dependent protein deacetylase and longevity factor SIRT1 inhibits NF-κB gene expression by deacetylating the RelA/p65 subunit of NF-κB at lysine 310.[45]

Non-canonical/alternate pathway

A select set of cell-differentiating or developmental stimuli, such as lymphotoxin β-receptor (LTβR), BAFF or RANKL, activate the non-canonical NF-κB pathway to induce NF-κB/RelB:p52 dimer in the nucleus. In this pathway, activation of the NF-κB inducing kinase (NIK) upon receptor ligation led to the phosphorylation and subsequent proteasomal processing of the NF-κB2 precursor protein p100 into mature p52 subunit in an IKK1/IKKa dependent manner. Then p52 dimerizes with RelB to appear as a nuclear RelB:p52 DNA binding activity. RelB:p52 regulates the expression of homeostatic lymphokines, which instructs lymphoid organogenesis and lymphocyte trafficking in the secondary lymphoid organs.[46] In contrast to the canonical signaling that relies on NEMO-IKK2 mediated degradation of IκBα, -β, -ε, non-canonical signaling depends on NIK mediated processing of p100 into p52. Given their distinct regulations, these two pathways were thought to be independent of each other. However, it was found that syntheses of the constituents of the non-canonical pathway, viz RelB and p52, are controlled by canonical IKK2-IκB-RelA:p50 signaling.[47] Moreover, generation of the canonical and non-canonical dimers, viz RelA:p50 and RelB:p52, within the cellular milieu are mechanistically interlinked.[47] These analyses suggest that an integrated NF-κB system network underlies activation of both RelA and RelB containing dimer and that a malfunctioning canonical pathway will lead to an aberrant cellular response also through the non-canonical pathway. Most intriguingly, a recent study identified that TNF-induced canonical signalling subverts non-canonical RelB:p52 activity in the inflamed lymphoid tissues limiting lymphocyte ingress.[48] Mechanistically, TNF inactivated NIK in LTβR‐stimulated cells and induced the synthesis of Nfkb2 mRNA encoding p100; these together potently accumulated unprocessed p100, which attenuated the RelB activity. A role of p100/Nfkb2 in dictating lymphocyte ingress in the inflamed lymphoid tissue may have broad physiological implications.

In addition to its traditional role in lymphoid organogenesis, the non-canonical NF-κB pathway also directly reinforces inflammatory immune responses to microbial pathogens by modulating canonical NF-κB signalling. It was shown that p100/Nfkb2 mediates stimulus-selective and cell-type-specific crosstalk between the two NF-κB pathways and that Nfkb2-mediated crosstalk protects mice from gut pathogens.[49][50] On the other hand, a lack of p100-mediated regulations repositions RelB under the control of TNF-induced canonical signalling. In fact, mutational inactivation of p100/Nfkb2 in multiple myeloma enabled TNF to induce a long-lasting RelB activity, which imparted resistance in myeloma cells to chemotherapeutic drug.[51]

In immunity

NF-κB is a major transcription factor that regulates genes responsible for both the innate and adaptive immune response.[52] Upon activation of either the T- or B-cell receptor, NF-κB becomes activated through distinct signaling components. Upon ligation of the T-cell receptor, protein kinase Lck is recruited and phosphorylates the ITAMs of the CD3 cytoplasmic tail. ZAP70 is then recruited to the phosphorylated ITAMs and helps recruit LAT and PLC-γ, which causes activation of PKC. Through a cascade of phosphorylation events, the kinase complex is activated and NF-κB is able to enter the nucleus to upregulate genes involved in T-cell development, maturation, and proliferation.[53]

In the nervous system

In addition to roles in mediating cell survival, studies by Mark Mattson and others have shown that NF-κB has diverse functions in the nervous system including roles in plasticity, learning, and memory.[54] In addition to stimuli that activate NF-κB in other tissues, NF-κB in the nervous system can be activated by Growth Factors (BDNF, NGF) and synaptic transmission such as glutamate.[9] These activators of NF-κB in the nervous system all converge upon the IKK complex and the canonical pathway.

Recently there has been a great deal of interest in the role of NF-κB in the nervous system. Current studies suggest that NF-κB is important for learning and memory in multiple organisms including crabs,[11][12] fruit flies,[55] and mice.[9][10] NF-κB may regulate learning and memory in part by modulating synaptic plasticity,[8][56] synapse function,[55][57][58] as well as by regulating the growth of dendrites[59] and dendritic spines.[58]

Genes that have NF-κB binding sites are shown to have increased expression following learning,[10] suggesting that the transcriptional targets of NF-κB in the nervous system are important for plasticity. Many NF-κB target genes that may be important for plasticity and learning include growth factors (BDNF, NGF)[60] cytokines (TNF-alpha, TNFR)[61] and kinases (PKAc).[56]

Despite the functional evidence for a role for Rel-family transcription factors in the nervous system, it is still not clear that the neurological effects of NF-κB reflect transcriptional activation in neurons. Most manipulations and assays are performed in the mixed-cell environments found in vivo, in "neuronal" cell cultures that contain significant numbers of glia, or in tumor-derived "neuronal" cell lines. When transfections or other manipulations have been targeted specifically at neurons, the endpoints measured are typically electrophysiology or other parameters far removed from gene transcription. Careful tests of NF-κB-dependent transcription in highly purified cultures of neurons generally show little to no NF-κB activity.[62][63]

Some of the reports of NF-κB in neurons appear to have been an artifact of antibody nonspecificity.[64] Of course, artifacts of cell culture—e.g., removal of neurons from the influence of glia—could create spurious results as well. But this has been addressed in at least two co-culture approaches. Moerman et al.[65] used a coculture format whereby neurons and glia could be separated after treatment for EMSA analysis, and they found that the NF-κB induced by glutamatergic stimuli was restricted to glia (and, intriguingly, only glia that had been in the presence of neurons for 48 hours). The same investigators explored the issue in another approach, utilizing neurons from an NF-κB reporter transgenic mouse cultured with wild-type glia; glutamatergic stimuli again failed to activate in neurons.[66] Some of the DNA-binding activity noted under certain conditions (particularly that reported as constitutive) appears to result from Sp3 and Sp4 binding to a subset of κB enhancer sequences in neurons.[67] This activity is actually inhibited by glutamate and other conditions that elevate intraneuronal calcium. In the final analysis, the role of NF-κB in neurons remains opaque due to the difficulty of measuring transcription in cells that are simultaneously identified for type. Certainly, learning and memory could be influenced by transcriptional changes in astrocytes and other glial elements. And it should be considered that there could be mechanistic effects of NF-κB aside from direct transactivation of genes.

Clinical significance

Overview of signal transduction pathways involved in apoptosis.

Cancers

NF-κB is widely used by eukaryotic cells as a regulator of genes that control cell proliferation and cell survival. As such, many different types of human tumors have misregulated NF-κB: that is, NF-κB is constitutively active. Active NF-κB turns on the expression of genes that keep the cell proliferating and protect the cell from conditions that would otherwise cause it to die via apoptosis. In cancer, proteins that control NF-κB signaling are mutated or aberrantly expressed, leading to defective coordination between the malignant cell and the rest of the organism. This is evident both in metastasis, as well as in the inefficient eradication of the tumor by the immune system.[68]

Normal cells can die when removed from the tissue they belong to, or when their genome cannot operate in harmony with tissue function: these events depend on feedback regulation of NF-κB, and fail in cancer.[69]

Defects in NF-κB results in increased susceptibility to apoptosis leading to increased cell death. This is because NF-κB regulates anti-apoptotic genes especially the TRAF1 and TRAF2 and therefore abrogates the activities of the caspase family of enzymes, which are central to most apoptotic processes.[70]

In tumor cells, NF-κB activity is enhanced, as for example, in 41% of nasopharyngeal carcinoma,[71] colorectal cancer, prostate cancer and pancreatic tumors. This is either due to mutations in genes encoding the NF-κB transcription factors themselves or in genes that control NF-κB activity (such as IκB genes); in addition, some tumor cells secrete factors that cause NF-κB to become active.[72][73] Blocking NF-κB can cause tumor cells to stop proliferating, to die, or to become more sensitive to the action of anti-tumor agents.[74][75] Thus, NF-κB is the subject of much active research among pharmaceutical companies as a target for anti-cancer therapy.[76]

However, even though convincing experimental data have identified NF-κB as a critical promoter of tumorigenesis, which creates a solid rationale for the development of antitumor therapy that is based upon suppression of NF-κB activity, caution should be exercised when considering anti-NF-κB activity as a broad therapeutic strategy in cancer treatment as data has also shown that NF-κB activity enhances tumor cell sensitivity to apoptosis and senescence. In addition, it has been shown that canonical NF-κB is a Fas transcription activator and the alternative NF-κB is a Fas transcription repressor.[77] Therefore, NF-κB promotes Fas-mediated apoptosis in cancer cells, and thus inhibition of NF-κB may suppress Fas-mediated apoptosis to impair host immune cell-mediated tumor suppression.

Inflammation

Because NF-κB controls many genes involved in inflammation, it is not surprising that NF-κB is found to be chronically active in many inflammatory diseases, such as inflammatory bowel disease, arthritis, sepsis, gastritis, asthma, atherosclerosis[78] and others. It is important to note though, that elevation of some NF-κB activators, such as osteoprotegerin (OPG), are associated with elevated mortality, especially from cardiovascular diseases.[79][80] Elevated NF-κB has also been associated with schizophrenia.[81] Recently, NF-κB activation has been suggested as a possible molecular mechanism for the catabolic effects of cigarette smoke in skeletal muscle and sarcopenia.[82] Research has shown that during inflammation the function of a cell depends on signals it activates in response to contact with adjacent cells and to combinations of hormones, especially cytokines that act on it through specific receptors.[83] A cell's phenotype within a tissue develops through mutual stimulation of feedback signals that coordinate its function with other cells; this is especially evident during reprogramming of cell function when a tissue is exposed to inflammation, because cells alter their phenotype, and gradually express combinations of genes that prepare the tissue for regeneration after the cause of inflammation is removed.[83][84] Particularly important are feedback responses that develop between tissue resident cells, and circulating cells of the immune system.[84]

Fidelity of feedback responses between diverse cell types and the immune system depends on the integrity of mechanisms that limit the range of genes activated by NF-κB, allowing only expression of genes which contribute to an effective immune response and subsequently, a complete restoration of tissue function after resolution of inflammation.[84] In cancer, mechanisms that regulate gene expression in response to inflammatory stimuli are altered to the point that a cell ceases to link its survival with the mechanisms that coordinate its phenotype and its function with the rest of the tissue.[69] This is often evident in severely compromised regulation of NF-κB activity, which allows cancer cells to express abnormal cohorts of NF-κB target genes.[85] This results in not only the cancer cells functioning abnormally: cells of surrounding tissue alter their function and cease to support the organism exclusively. Additionally, several types of cells in the microenvironment of cancer may change their phenotypes to support cancer growth.[86][87][88] Inflammation, therefore, is a process that tests the fidelity of tissue components because the process that leads to tissue regeneration requires coordination of gene expression between diverse cell types.[83][89]

NEMO

NEMO deficiency syndrome is a rare genetic condition relating to a fault in IKBKG that in turn activates NF-κB. It mostly affects males and has a highly variable set of symptoms and prognoses.[90]

Aging and obesity

NF-κB is increasingly expressed with obesity and aging,[91] resulting in reduced levels of the anti-inflammatory, pro-autophagy, anti-insulin resistance protein sirtuin 1. NF-κB increases the levels of the microRNA miR-34a, which inhibits nicotinamide adenine dinucleotide (NAD) synthesis by binding to its promoter region,[92] resulting in lower levels of sirtuin 1.

NF-κB and interleukin 1 alpha mutually induce each other in senescent cells in a positive feedback loop causing the production of senescence-associated secretory phenotype (SASP) factors.[93] NF-κB and the NAD-degrading enzyme CD38 also mutually induce each other.[94]

NF-κB is a central component of the cellular response to damage.[95] NF-κB is activated in a variety of cell types that undergo normal or accelerated aging.[95] Genetic or pharmacologic inhibition of NF-κB activation can delay the onset of numerous aging related symptoms and pathologies.[95] This effect may be explained, in part, by the finding that reduction of NF-κB reduces the production of mitochondria-derived reactive oxygen species that can damage DNA.[95]

Addiction

NF-κB is one of several induced transcriptional targets of ΔFosB which facilitates the development and maintenance of an addiction to a stimulus.[96][97][98] In the caudate putamen, NF-κB induction is associated with increases in locomotion, whereas in the nucleus accumbens, NF-κB induction enhances the positive reinforcing effect of a drug through reward sensitization.[97]

Neural and behavioral effects of validated ΔFosB transcriptional targets[97][99]
Target
gene 		Target
expression 		Neural effects Behavioral effects
c-Fos ↓ Molecular switch enabling the chronic
induction of ΔFosB[note 1]		 –
dynorphin ↓
[note 2]		  • Downregulation of κ-opioid feedback loop  • Decreased drug aversion
NF-κB ↑  • Expansion of NAcc dendritic processes
 • NF-κB inflammatory response in the NAcc
 • NF-κB inflammatory response in the CP		  • Increased drug reward
 • Increased drug reward
 • Locomotor sensitization
GluR2 ↑  • Decreased sensitivity to glutamate  • Increased drug reward
Cdk5 ↑  • GluR1 synaptic protein phosphorylation
 • Expansion of NAcc dendritic processes		 Decreased drug reward
(net effect)

Non-drug inhibitors

Many natural products (including anti-oxidants) that have been promoted to have anti-cancer and anti-inflammatory activity have also been shown to inhibit NF-κB. There is a controversial US patent (US patent 6,410,516)[100] that applies to the discovery and use of agents that can block NF-κB for therapeutic purposes. This patent is involved in several lawsuits, including Ariad v. Lilly. Recent work by Karin,[101] Ben-Neriah[102] and others has highlighted the importance of the connection between NF-κB, inflammation, and cancer, and underscored the value of therapies that regulate the activity of NF-κB.[103]

Extracts from a number of herbs and dietary plants are efficient inhibitors of NF-κB activation in vitro.[104] Nobiletin, a flavonoid isolated from citrus peels, has been shown to inhibit the NF-κB signaling pathway in mice.[105] The circumsporozoite protein of Plasmodium falciparum has been shown to be an inhibitor of NF-κB.[106] Likewise, various withanolides of Withania somnifera (Ashwagandha) have been found to have inhibiting effects on NF-κB through inhibition of proteasome mediated ubiquitin degradation of IκBα.[107][108]

As a drug target

Aberrant activation of NF-κB is frequently observed in many cancers. Moreover, suppression of NF-κB limits the proliferation of cancer cells. In addition, NF-κB is a key player in the inflammatory response. Hence methods of inhibiting NF-κB signaling has potential therapeutic application in cancer and inflammatory diseases.[109][110]

Both the canonical and non-canonical NF-κB pathways require proteasomal degradation of regulatory pathway components for NF-κB signalling to occur. The proteosome inhibitor Bortezomib broadly blocks this activity and is approved for treatment of NF-κB driven Mantle Cell Lymphoma and Multiple Myeloma.[111][112]

The discovery that activation of NF-κB nuclear translocation can be separated from the elevation of oxidant stress[113] gives a promising avenue of development for strategies targeting NF-κB inhibition.

The drug denosumab acts to raise bone mineral density and reduce fracture rates in many patient sub-groups by inhibiting RANKL. RANKL acts through its receptor RANK, which in turn promotes NF-κB,[114] RANKL normally works by enabling the differentiation of osteoclasts from monocytes.

Disulfiram, olmesartan and dithiocarbamates can inhibit the NF-κB signaling cascade.[115] Effort to develop direct NF-κB inhibitor has emerged with compounds such as (-)-DHMEQ, PBS-1086, IT-603 and IT-901.[116][117][118] (-)-DHMEQ and PBS-1086 are irreversible binder to NF-κB while IT-603 and IT-901 are reversible binder. DHMEQ covalently binds to Cys 38 of p65.[119]

Anatabine's antiinflammatory effects are claimed to result from modulation of NF-κB activity.[120] However the studies purporting its benefit use abnormally high doses in the millimolar range (similar to the extracellular potassium concentration), which are unlikely to be achieved in humans.

BAY 11-7082 has also been identified as a drug that can inhibit the NF-κB signaling cascade. It is capable of preventing the phosphorylation of IKK-α in an irreversible manner such that there is down regulation of NF-κB activation.[121]

It has been shown that administration of BAY 11-7082 rescued renal functionality in diabetic-induced Sprague-Dawley rats by suppressing NF-κB regulated oxidative stress.[122]

Research has shown that the N-acylethanolamine, palmitoylethanolamide is capable of PPAR-mediated inhibition of NF-κB.[123]

The biological target of iguratimod, a drug marketed to treat rheumatoid arthritis in Japan and China, was unknown as of 2015, but the primary mechanism of action appeared to be preventing NF-κB activation.[124]

See also

Notes

  1. ↑ In other words, c-Fos repression allows ΔFosB to accumulate within nucleus accumbens medium spiny neurons more rapidly because it is selectively induced in this state.[98]
  2. ↑ ΔFosB has been implicated in causing both increases and decreases in dynorphin expression in different studies;[97][99] this table entry reflects only a decrease.

References

  1. ↑ 1.0 1.1 1.2 "NF-κB Rel subunit exchange on a physiological timescale". Protein Science 30 (9): 1818–1832. September 2021. doi:10.1002/pro.4134. PMID 34089216. 
  2. ↑ 2.0 2.1 2.2 2.3 2.4 "Introduction to NF-kappaB: players, pathways, perspectives". Oncogene 25 (51): 6680–6684. October 2006. doi:10.1038/sj.onc.1209954. PMID 17072321. 
  3. ↑ 3.0 3.1 3.2 "The NF-kappaB regulatory network". Cardiovascular Toxicology 6 (2): 111–130. 2006. doi:10.1385/CT:6:2:111. PMID 17303919. 
  4. ↑ 4.0 4.1 4.2 "Integrating cell-signalling pathways with NF-kappaB and IKK function". Nature Reviews. Molecular Cell Biology 8 (1): 49–62. January 2007. doi:10.1038/nrm2083. PMID 17183360. 
  5. ↑ 5.0 5.1 "NFKB1 and Cancer: Friend or Foe?". Cells 7 (9): 133. September 2018. doi:10.3390/cells7090133. PMID 30205516. 
  6. ↑ "The Rel/NF-kappaB signal transduction pathway: introduction". Oncogene 18 (49): 6842–6844. November 1999. doi:10.1038/sj.onc.1203237. PMID 10602459. 
  7. ↑ "Identification of a nuclear factor kappa B-dependent gene network". Recent Progress in Hormone Research 58: 95–130. 2003. doi:10.1210/rp.58.1.95. PMID 12795416. 
  8. ↑ 8.0 8.1 "Evidence for the involvement of TNF and NF-kappaB in hippocampal synaptic plasticity". Synapse 35 (2): 151–159. February 2000. doi:10.1002/(SICI)1098-2396(200002)35:2<151::AID-SYN8>3.0.CO;2-P. PMID 10611641. 
  9. ↑ 9.0 9.1 9.2 "NF-kappa B functions in synaptic signaling and behavior". Nature Neuroscience 6 (10): 1072–1078. October 2003. doi:10.1038/nn1110. PMID 12947408. 
  10. ↑ 10.0 10.1 10.2 "A bioinformatics analysis of memory consolidation reveals involvement of the transcription factor c-rel". The Journal of Neuroscience 24 (16): 3933–3943. April 2004. doi:10.1523/JNEUROSCI.5646-03.2004. PMID 15102909. 
  11. ↑ 11.0 11.1 "Kappa-B like DNA-binding activity is enhanced after spaced training that induces long-term memory in the crab Chasmagnathus". Neuroscience Letters 242 (3): 143–146. February 1998. doi:10.1016/S0304-3940(98)00059-7. PMID 9530926. 
  12. ↑ 12.0 12.1 "The IkappaB kinase inhibitor sulfasalazine impairs long-term memory in the crab Chasmagnathus". Neuroscience 112 (1): 161–172. 2002. doi:10.1016/S0306-4522(02)00049-0. PMID 12044481. 
  13. ↑ "Mercury induces the expression of cyclooxygenase-2 and inducible nitric oxide synthase". Toxicology and Industrial Health 29 (2): 169–174. March 2013. doi:10.1177/0748233711427048. PMID 22080037. 
  14. ↑ "Multiple nuclear factors interact with the immunoglobulin enhancer sequences". Cell 46 (5): 705–716. August 1986. doi:10.1016/0092-8674(86)90346-6. PMID 3091258. 
  15. ↑ "Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene". Science 282 (5396): 2085–2088. December 1998. doi:10.1126/science.282.5396.2085. PMID 9851930. 
  16. ↑ "The dorsoventral regulatory gene cassette spätzle/Toll/cactus controls the potent antifungal response in Drosophila adults". Cell 86 (6): 973–983. September 1996. doi:10.1016/s0092-8674(00)80172-5. PMID 8808632. 
  17. ↑ "The Nobel Prize in Physiology or Medicine 2011" (in en-US). https://www.nobelprize.org/prizes/medicine/2011/summary/. 
  18. ↑ "Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity". Annual Review of Immunology 18: 621–663. 2000. doi:10.1146/annurev.immunol.18.1.621. PMID 10837071. 
  19. ↑ "Activation by IKKalpha of a second, evolutionary conserved, NF-kappa B signaling pathway". Science 293 (5534): 1495–1499. August 2001. doi:10.1126/science.1062677. PMID 11520989. Bibcode: 2001Sci...293.1495S. 
  20. ↑ "KBF1 (p50 NF-kappa B homodimer) acts as a repressor of H-2Kb gene expression in metastatic tumor cells". The Journal of Experimental Medicine 177 (6): 1651–1662. June 1993. doi:10.1084/jem.177.6.1651. PMID 8496683. 
  21. ↑ "DNA binding of repressor nuclear factor-kappaB p50/p50 depends on phosphorylation of Ser337 by the protein kinase A catalytic subunit". The Journal of Biological Chemistry 280 (11): 9957–9962. March 2005. doi:10.1074/jbc.m412180200. PMID 15642694. 
  22. ↑ "Proposed NF-kappa B/I kappa B family nomenclature". Genes & Development 7 (11): 2063. November 1993. doi:10.1101/gad.7.11.2063. PMID 8224837. 
  23. ↑ "NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses". Annual Review of Immunology 16: 225–260. 1998. doi:10.1146/annurev.immunol.16.1.225. PMID 9597130. 
  24. ↑ "Evolutionary dynamics of immune-related genes and pathways in disease-vector mosquitoes". Science 316 (5832): 1738–1743. June 2007. doi:10.1126/science.1139862. PMID 17588928. Bibcode: 2007Sci...316.1738W. 
  25. ↑ PDB: 3do7​; "NF-kappaB p52:RelB heterodimer recognizes two classes of kappaB sites with two distinct modes". EMBO Reports 10 (2): 152–159. February 2009. doi:10.1038/embor.2008.227. PMID 19098713. 
  26. ↑ (a) "Role of oxidants in NF-kappa B activation and TNF-alpha gene transcription induced by hypoxia and endotoxin". Journal of Immunology 165 (2): 1013–1021. July 2000. doi:10.4049/jimmunol.165.2.1013. PMID 10878378. ; (b) "Tumour necrosis factor-alpha (TNF-alpha) increases nuclear factor kappaB (NFkappaB) activity in and interleukin-8 (IL-8) release from bovine mammary epithelial cells". Veterinary Immunology and Immunopathology 116 (1–2): 59–68. March 2007. doi:10.1016/j.vetimm.2006.12.008. PMID 17276517. ; (c) "Effects of antioxidant enzyme modulations on interleukin-1-induced nuclear factor kappa B activation". Biochemical Pharmacology 53 (2): 149–160. January 1997. doi:10.1016/S0006-2952(96)00645-4. PMID 9037247. ; (d) "LPS induces CD40 gene expression through the activation of NF-kappaB and STAT-1alpha in macrophages and microglia". Blood 106 (9): 3114–3122. November 2005. doi:10.1182/blood-2005-02-0759. PMID 16020513. ; (e) "Increased JNK, AP-1 and NF-kappa B DNA binding activities in isoproterenol-induced cardiac remodeling". Journal of Molecular and Cellular Cardiology 31 (11): 2017–2030. November 1999. doi:10.1006/jmcc.1999.1033. PMID 10591028. ; (f) "Cocaine, not morphine, causes the generation of reactive oxygen species and activation of NF-kappaB in transiently cotransfected heart cells". Cardiovascular Toxicology 3 (2): 141–151. 2003. doi:10.1385/CT:3:2:141. PMID 14501032. ; (g) "Role of endothelin and endothelin receptor antagonists in renal disease". European Journal of Clinical Investigation 36 (Supplementary 3): 78–88. September 2006. doi:10.1111/j.1365-2362.2006.01689.x. PMID 16919017. ; (h) "The DNA-dependent protein kinase participates in the activation of NF kappa B following DNA damage". Biochemical and Biophysical Research Communications 247 (1): 79–83. June 1998. doi:10.1006/bbrc.1998.8741. PMID 9636658. 
  27. ↑ "The NF-kappaB-mediated control of the JNK cascade in the antagonism of programmed cell death in health and disease". Cell Death and Differentiation 13 (5): 712–729. May 2006. doi:10.1038/sj.cdd.4401865. PMID 16456579. 
  28. ↑ "RANKL, RANK, osteoprotegerin: key partners of osteoimmunology and vascular diseases". Cellular and Molecular Life Sciences 64 (18): 2334–2350. September 2007. doi:10.1007/s00018-007-7104-0. PMID 17530461. 
  29. ↑ "Toll-like receptors: from the discovery of NFkappaB to new insights into transcriptional regulations in innate immunity". Biochemical Pharmacology 72 (9): 1102–1113. October 2006. doi:10.1016/j.bcp.2006.07.010. PMID 16930560. 
  30. ↑ "NF-kappaB and the immune response". Oncogene 25 (51): 6758–6780. October 2006. doi:10.1038/sj.onc.1209943. PMID 17072327. 
  31. ↑ "NF-kappaB regulation in the immune system". Nature Reviews. Immunology 2 (10): 725–734. October 2002. doi:10.1038/nri910. PMID 12360211. 
  32. ↑ "The candidate proto-oncogene bcl-3 encodes a transcriptional coactivator that activates through NF-kappa B p50 homodimers". Genes & Development 7 (7B): 1354–1363. July 1993. doi:10.1101/gad.7.7b.1354. PMID 8330739. 
  33. ↑ "The candidate oncoprotein Bcl-3 is an antagonist of p50/NF-kappa B-mediated inhibition". Nature 359 (6393): 339–342. September 1992. doi:10.1038/359339a0. PMID 1406939. Bibcode: 1992Natur.359..339F. https://zenodo.org/record/1233131. 
  34. ↑ "The oncoprotein Bcl-3 directly transactivates through kappa B motifs via association with DNA-binding p50B homodimers". Cell 72 (5): 729–739. March 1993. doi:10.1016/0092-8674(93)90401-B. PMID 8453667. 
  35. ↑ "Structure of an IkappaBalpha/NF-kappaB complex". Cell 95 (6): 749–758. December 1998. doi:10.1016/S0092-8674(00)81698-0. PMID 9865693. 
  36. ↑ 36.0 36.1 "A fourth IkappaB protein within the NF-kappaB signaling module". Cell 128 (2): 369–381. January 2007. doi:10.1016/j.cell.2006.12.033. PMID 17254973. .
  37. ↑ "Specific inhibition of RelB/p52 transcriptional activity by the C-terminal domain of p100". Oncogene 10 (5): 1003–1007. March 1995. PMID 7898917. 
  38. ↑ "Coordination between NF-kappaB family members p50 and p52 is essential for mediating LTbetaR signals in the development and organization of secondary lymphoid tissues". Blood 107 (3): 1048–1055. February 2006. doi:10.1182/blood-2005-06-2452. PMID 16195333. 
  39. ↑ "Activation of nuclear factor kappa B (NF-kappaB) assayed by laser scanning cytometry (LSC)". Cytometry 33 (3): 376–382. November 1998. doi:10.1002/(SICI)1097-0320(19981101)33:3<376::AID-CYTO13>3.0.CO;2-Q. PMID 9822350. 
  40. ↑ "Oscillations in NF-kappaB signaling control the dynamics of gene expression". Science 306 (5696): 704–708. October 2004. doi:10.1126/science.1099962. PMID 15499023. Bibcode: 2004Sci...306..704N. 
  41. ↑ "Hostile takeovers: viral appropriation of the NF-kappaB pathway". The Journal of Clinical Investigation 107 (2): 143–151. January 2001. doi:10.1172/JCI11918. PMID 11160127. 
  42. ↑ "Differential roles of Yersinia outer protein P-mediated inhibition of nuclear factor-kappa B in the induction of cell death in dendritic cells and macrophages". Journal of Medical Microbiology 57 (Pt 2): 139–144. February 2008. doi:10.1099/jmm.0.47437-0. PMID 18201977. 
  43. ↑ "PC4 coactivates MyoD by relieving the histone deacetylase 4-mediated inhibition of myocyte enhancer factor 2C". Molecular and Cellular Biology 25 (6): 2242–2259. March 2005. doi:10.1128/MCB.25.6.2242-2259.2005. PMID 15743821. 
  44. ↑ "PC4/Tis7/IFRD1 stimulates skeletal muscle regeneration and is involved in myoblast differentiation as a regulator of MyoD and NF-kappaB". The Journal of Biological Chemistry 286 (7): 5691–5707. February 2011. doi:10.1074/jbc.M110.162842. PMID 21127072. 
  45. ↑ "Modulation of NF-kappaB-dependent transcription and cell survival by the SIRT1 deacetylase". The EMBO Journal 23 (12): 2369–2380. June 2004. doi:10.1038/sj.emboj.7600244. PMID 15152190. 
  46. ↑ "Activation of IKKalpha target genes depends on recognition of specific kappaB binding sites by RelB:p52 dimers". The EMBO Journal 23 (21): 4202–4210. October 2004. doi:10.1038/sj.emboj.7600391. PMID 15470505. 
  47. ↑ 47.0 47.1 "Generation and activation of multiple dimeric transcription factors within the NF-kappaB signaling system". Molecular and Cellular Biology 28 (10): 3139–3150. May 2008. doi:10.1128/MCB.01469-07. PMID 18299388. 
  48. ↑ "A TNF-p100 pathway subverts noncanonical NF-κB signaling in inflamed secondary lymphoid organs". The EMBO Journal 36 (23): 3501–3516. December 2017. doi:10.15252/embj.201796919. PMID 29061763. 
  49. ↑ "Stimulus-selective crosstalk via the NF-κB signaling system reinforces innate immune response to alleviate gut infection". eLife 4: e05648. April 2015. doi:10.7554/eLife.05648. PMID 25905673. 
  50. ↑ "Late-phase synthesis of IκBα insulates the TLR4-activated canonical NF-κB pathway from noncanonical NF-κB signaling in macrophages". Science Signaling 9 (457): ra120. December 2016. doi:10.1126/scisignal.aaf1129. PMID 27923915. 
  51. ↑ "Non-canonical NFκB mutations reinforce pro-survival TNF response in multiple myeloma through an autoregulatory RelB:p50 NFκB pathway". Oncogene 36 (10): 1417–1429. March 2017. doi:10.1038/onc.2016.309. PMID 27641334. 
  52. ↑ "Corticotropin Releasing Factor (CRF) activation of NF-kappaB-directed transcription in leukocytes". Cellular and Molecular Neurobiology 26 (4–6): 1021–1036. 2006-07-01. doi:10.1007/s10571-006-9040-1. PMID 16633893. 
  53. ↑ "Tyrosine phosphorylation-dependent activation of NF-kappa B. Requirement for p56 LCK and ZAP-70 protein tyrosine kinases". European Journal of Biochemistry 268 (5): 1508–1515. March 2001. doi:10.1046/j.1432-1327.2001.02028.x. PMID 11231305. 
  54. ↑ "Roles for NF-kappaB in nerve cell survival, plasticity, and disease". Cell Death and Differentiation 13 (5): 852–860. May 2006. doi:10.1038/sj.cdd.4401837. PMID 16397579. 
  55. ↑ 55.0 55.1 "NF-kappaB, IkappaB, and IRAK control glutamate receptor density at the Drosophila NMJ". Neuron 55 (6): 859–873. September 2007. doi:10.1016/j.neuron.2007.08.005. PMID 17880891. 
  56. ↑ 56.0 56.1 "NF-kappaB regulates spatial memory formation and synaptic plasticity through protein kinase A/CREB signaling". Molecular and Cellular Biology 26 (8): 2936–2946. April 2006. doi:10.1128/MCB.26.8.2936-2946.2006. PMID 16581769. 
  57. ↑ "Nuclear factor kappaB controls acetylcholine receptor clustering at the neuromuscular junction". The Journal of Neuroscience 30 (33): 11104–11113. August 2010. doi:10.1523/JNEUROSCI.2118-10.2010. PMID 20720118. 
  58. ↑ 58.0 58.1 "A requirement for nuclear factor-kappaB in developmental and plasticity-associated synaptogenesis". The Journal of Neuroscience 31 (14): 5414–5425. April 2011. doi:10.1523/JNEUROSCI.2456-10.2011. PMID 21471377. 
  59. ↑ "NF-kappaB signalling regulates the growth of neural processes in the developing PNS and CNS". Development 132 (7): 1713–1726. April 2005. doi:10.1242/dev.01702. PMID 15743881. 
  60. ↑ "Effects of glia maturation factor overexpression in primary astrocytes on MAP kinase activation, transcription factor activation, and neurotrophin secretion". Neurochemical Research 26 (12): 1293–1299. December 2001. doi:10.1023/A:1014241300179. PMID 11885780. 
  61. ↑ "Effects of NF-kappaB oligonucleotide "decoys" on gene expression in P7 rat hippocampus after hypoxia/ischemia". Journal of Neuroscience Research 77 (1): 108–118. July 2004. doi:10.1002/jnr.20156. PMID 15197744. 
  62. ↑ "Minimal NF-κB activity in neurons". Neuroscience 250: 282–299. October 2013. doi:10.1016/j.neuroscience.2013.07.013. PMID 23872390. 
  63. ↑ "Specific deficiency in nuclear factor-kappaB activation in neurons of the central nervous system". Laboratory Investigation; A Journal of Technical Methods and Pathology 81 (9): 1275–1288. September 2001. doi:10.1038/labinvest.3780341. PMID 11555675. 
  64. ↑ "Cautionary notes on the use of NF-κB p65 and p50 antibodies for CNS studies". Journal of Neuroinflammation 8: 141. October 2011. doi:10.1186/1742-2094-8-141. PMID 21999414. 
  65. ↑ "Characterization of a neuronal kappaB-binding factor distinct from NF-kappaB". Brain Research. Molecular Brain Research 67 (2): 303–315. April 1999. doi:10.1016/s0169-328x(99)00091-1. PMID 10216229. 
  66. ↑ "Unique aspects of transcriptional regulation in neurons--nuances in NFkappaB and Sp1-related factors". Journal of Neuroinflammation 6: 16. May 2009. doi:10.1186/1742-2094-6-16. PMID 19450264. 
  67. ↑ "Glutamate receptor activation evokes calpain-mediated degradation of Sp3 and Sp4, the prominent Sp-family transcription factors in neurons". Journal of Neurochemistry 100 (5): 1300–1314. March 2007. doi:10.1111/j.1471-4159.2006.04297.x. PMID 17316402. 
  68. ↑ "Aberrant control of NF-κB in cancer permits transcriptional and phenotypic plasticity, to curtail dependence on host tissue: molecular mode". Cancer Biology & Medicine 14 (3): 254–270. August 2017. doi:10.20892/j.issn.2095-3941.2017.0029. PMID 28884042. 
  69. ↑ 69.0 69.1 "Dynamic aberrant NF-κB spurs tumorigenesis: a new model encompassing the microenvironment". Cytokine & Growth Factor Reviews 26 (4): 389–403. August 2015. doi:10.1016/j.cytogfr.2015.06.001. PMID 26119834. 
  70. ↑ "Death receptor activation complexes: it takes two to activate TNF receptor 1". Cell Cycle 2 (6): 550–552. 2003. doi:10.4161/cc.2.6.566. PMID 14504472. 
  71. ↑ "Exome and genome sequencing of nasopharynx cancer identifies NF-κB pathway activating mutations". Nature Communications 8: 14121. January 2017. doi:10.1038/ncomms14121. PMID 28098136. Bibcode: 2017NatCo...814121L. 
  72. ↑ "Non-canonical NF-κB signaling pathway". Cell Research 21 (1): 71–85. January 2011. doi:10.1038/cr.2010.177. PMID 21173796. 
  73. ↑ "Transient Sox9 Expression Facilitates Resistance to Androgen-Targeted Therapy in Prostate Cancer". Clinical Cancer Research 26 (7): 1678–1689. April 2020. doi:10.1158/1078-0432.CCR-19-0098. PMID 31919137. 
  74. ↑ "NF-κB, inflammation, immunity and cancer: coming of age". Nature Reviews. Immunology 18 (5): 309–324. May 2018. doi:10.1038/nri.2017.142. PMID 29379212. 
  75. ↑ "Epigenetic regulation of SOX9 by the NF-κB signaling pathway in pancreatic cancer stem cells". Stem Cells 31 (8): 1454–1466. August 2013. doi:10.1002/stem.1394. PMID 23592398. 
  76. ↑ "The transcription factor nuclear factor-kappa B and cancer". Clinical Oncology 19 (2): 154–161. March 2007. doi:10.1016/j.clon.2006.11.013. PMID 17355113. 
  77. ↑ "NF-κB directly regulates Fas transcription to modulate Fas-mediated apoptosis and tumor suppression". The Journal of Biological Chemistry 287 (30): 25530–25540. July 2012. doi:10.1074/jbc.M112.356279. PMID 22669972. 
  78. ↑ "Canonical pathway of nuclear factor kappa B activation selectively regulates proinflammatory and prothrombotic responses in human atherosclerosis". Proceedings of the National Academy of Sciences of the United States of America 101 (15): 5634–5639. April 2004. doi:10.1073/pnas.0401060101. PMID 15064395. Bibcode: 2004PNAS..101.5634M. 
  79. ↑ "Osteoprotegerin as a predictor of coronary artery disease and cardiovascular mortality and morbidity". Journal of the American College of Cardiology 55 (19): 2049–2061. May 2010. doi:10.1016/j.jacc.2010.03.013. PMID 20447527. 
  80. ↑ "Biomarkers of the osteoprotegerin pathway: clinical correlates, subclinical disease, incident cardiovascular disease, and mortality". Arteriosclerosis, Thrombosis, and Vascular Biology 30 (9): 1849–1854. September 2010. doi:10.1161/ATVBAHA.109.199661. PMID 20448212. 
  81. ↑ "The interaction of nuclear factor-kappa B and cytokines is associated with schizophrenia". Biological Psychiatry 65 (6): 481–488. March 2009. doi:10.1016/j.biopsych.2008.10.018. PMID 19058794. 
  82. ↑ "Involvement of NF-κB and Muscle Specific E3 Ubiquitin Ligase MuRF1 in Cigarette Smoke-Induced Catabolism in C2 Myotubes". Neurobiology of Respiration. Advances in Experimental Medicine and Biology. 788. 2013. pp. 7–17. doi:10.1007/978-94-007-6627-3_2. ISBN 978-94-007-6626-6. 
  83. ↑ 83.0 83.1 83.2 "Endogenous modulators of inflammatory cell recruitment". Trends in Immunology 34 (1): 1–6. January 2013. doi:10.1016/j.it.2012.08.003. PMID 22951309. 
  84. ↑ 84.0 84.1 84.2 "The role of "anti-inflammatory" cytokines in axon regeneration". Cytokine & Growth Factor Reviews 24 (1): 1–12. February 2013. doi:10.1016/j.cytogfr.2012.08.008. PMID 22985997. 
  85. ↑ "Dangerous liaisons: STAT3 and NF-kappaB collaboration and crosstalk in cancer". Cytokine & Growth Factor Reviews 21 (1): 11–19. February 2010. doi:10.1016/j.cytogfr.2009.11.005. PMID 20018552. 
  86. ↑ "Phagocytes as Corrupted Policemen in Cancer-Related Inflammation". Advances in Cancer Research 128: 141–171. 2015. doi:10.1016/bs.acr.2015.04.013. ISBN 978-0-12-802316-7. PMID 26216632. 
  87. ↑ "The Multifaceted Roles Neutrophils Play in the Tumor Microenvironment". Cancer Microenvironment 8 (3): 125–158. December 2015. doi:10.1007/s12307-014-0147-5. PMID 24895166. 
  88. ↑ "Targeted destruction of the orchestration of the pancreatic stroma and tumor cells in pancreatic cancer cases: molecular basis for therapeutic implications". Cytokine & Growth Factor Reviews 23 (6): 343–356. December 2012. doi:10.1016/j.cytogfr.2012.06.006. PMID 22749856. 
  89. ↑ "A perspective on the role of class III semaphorin signaling in central nervous system trauma". Frontiers in Cellular Neuroscience 8: 328. 2014. doi:10.3389/fncel.2014.00328. PMID 25386118. 
  90. ↑ NEMO deficiency syndrome information NEMO deficiency syndrome information], Great Ormond Street Hospital for Children
  91. ↑ "Antagonistic crosstalk between NF-κB and SIRT1 in the regulation of inflammation and metabolic disorders". Cellular Signalling 25 (10): 1939–1948. October 2013. doi:10.1016/j.cellsig.2013.06.007. PMID 23770291. 
  92. ↑ "Relevance of SIRT1-NF-κB Axis as Therapeutic Target to Ameliorate Inflammation in Liver Disease". International Journal of Molecular Sciences 21 (11): 3858. May 2020. doi:10.3390/ijms21113858. PMID 32485811. 
  93. ↑ "Rapamycin inhibits the secretory phenotype of senescent cells by a Nrf2-independent mechanism". Aging Cell 16 (3): 564–574. June 2017. doi:10.1111/acel.12587. PMID 28371119. 
  94. ↑ "Macrophage Immunometabolism and Inflammaging: Roles of Mitochondrial Dysfunction, Cellular Senescence, CD38, and NAD". Immunometabolism 2 (3): e200026. June 2020. doi:10.20900/immunometab20200026. PMID 32774895. 
  95. ↑ 95.0 95.1 95.2 95.3 Tilstra JS, Robinson AR, Wang J, Gregg SQ, Clauson CL, Reay DP, Nasto LA, St Croix CM, Usas A, Vo N, Huard J, Clemens PR, Stolz DB, Guttridge DC, Watkins SC, Garinis GA, Wang Y, Niedernhofer LJ, Robbins PD. NF-κB inhibition delays DNA damage-induced senescence and aging in mice. J Clin Invest. 2012 Jul;122(7):2601-12. doi: 10.1172/JCI45785. Epub 2012 Jun 18. PMID: 22706308; PMCID: PMC3386805
  96. ↑ "Transcriptional and epigenetic mechanisms of addiction". Nature Reviews. Neuroscience 12 (11): 623–637. October 2011. doi:10.1038/nrn3111. PMID 21989194. 
  97. ↑ 97.0 97.1 97.2 97.3 "Molecular neurobiology of addiction: what's all the (Δ)FosB about?". The American Journal of Drug and Alcohol Abuse 40 (6): 428–437. November 2014. doi:10.3109/00952990.2014.933840. PMID 25083822. 
  98. ↑ 98.0 98.1 "Cellular basis of memory for addiction". Dialogues in Clinical Neuroscience 15 (4): 431–443. December 2013. doi:10.31887/DCNS.2013.15.4/enestler. PMID 24459410. 
  99. ↑ 99.0 99.1 "Review. Transcriptional mechanisms of addiction: role of DeltaFosB". Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences 363 (1507): 3245–3255. October 2008. doi:10.1098/rstb.2008.0067. PMID 18640924. 
    Table 3
  100. ↑ Baltimore D, Sen R, Sharp PA, Singh H, Staudt L, Lebowitz JH, Baldwin Jr AS, Clerc RG, Corcoran LM, Baeuerle PA, Lenardo MJ, Fan CM, Maniatis TP, "Nuclear factors associated with transcriptional regulation", US patent 6410516, issued 25 June 2002, assigned to Harvard College, Whitehead Institute for Biomedical Research, Massachusetts Institute of Technology
  101. ↑ "The IkappaB kinase – a bridge between inflammation and cancer". Cell Research 18 (3): 334–342. March 2008. doi:10.1038/cr.2008.30. PMID 18301380. 
  102. ↑ "NF-kappaB inhibition: a double-edged sword in cancer?". European Journal of Cancer 42 (6): 779–784. April 2006. doi:10.1016/j.ejca.2006.01.011. PMID 16530406. 
  103. ↑ "Linking Inflammation Reactions to Cancer: Novel Targets for Therapeutic Strategies". Targeted Therapies in Cancer. Advances in Experimental Medicine and Biology. 610. 2008. pp. 112–127. doi:10.1007/978-0-387-73898-7_9. ISBN 978-0-387-73897-0. 
  104. ↑ "Extract of oregano, coffee, thyme, clove, and walnuts inhibits NF-kappaB in monocytes and in transgenic reporter mice". Cancer Prevention Research 3 (5): 653–663. May 2010. doi:10.1158/1940-6207.CAPR-09-0089. PMID 20424131. 
  105. ↑ "Nobiletin Inhibits IL-1β-Induced Inflammation in Chondrocytes via Suppression of NF-κB Signaling and Attenuates Osteoarthritis in Mice". Frontiers in Pharmacology 10: 570. 2019. doi:10.3389/fphar.2019.00570. PMID 31214026. 
  106. ↑ "The Plasmodium circumsporozoite protein, a novel NF-κB inhibitor, suppresses the growth of SW480". Pathology & Oncology Research 18 (4): 895–902. October 2012. doi:10.1007/s12253-012-9519-7. PMID 22678765. 
  107. ↑ "Natural Withanolides in the Treatment of Chronic Diseases". Anti-inflammatory Nutraceuticals and Chronic Diseases. Advances in Experimental Medicine and Biology. 928. Springer International Publishing. 2016. pp. 329–373. doi:10.1007/978-3-319-41334-1_14. ISBN 978-3-319-41332-7. 
  108. ↑ "Pharmacological Effects of Withanolides" (in English). Biomedical Journal of Scientific & Technical Research 25 (3): 19243–19248. 2020-02-11. doi:10.26717/BJSTR.2020.25.004218. ISSN 2574-1241. https://biomedres.us/fulltexts/BJSTR.MS.ID.004218.php. 
  109. ↑ "Nuclear transcription factor-kappaB as a target for cancer drug development". Leukemia 16 (6): 1053–1068. June 2002. doi:10.1038/sj.leu.2402482. PMID 12040437. 
  110. ↑ "Nuclear factor-kappaB activation: from bench to bedside". Experimental Biology and Medicine 233 (1): 21–31. January 2008. doi:10.3181/0707-MR-196. PMID 18156302. 
  111. ↑ "Bortezomib: a review of its use in patients with multiple myeloma". Drugs 69 (7): 859–888. 2009. doi:10.2165/00003495-200969070-00006. PMID 19441872. 
  112. ↑ "Velcade (Bortezomib) Receives 2 New FDA Indications: For Retreatment of Patients with Multiple Myeloma and for First-Line Treatment of Patients with Mantle-Cell Lymphoma". American Health & Drug Benefits 8 (Spec Feature): 135–140. March 2015. PMID 26629279. 
  113. ↑ "Nuclear factor-kappaB-dependent induction of interleukin-8 gene expression by tumor necrosis factor alpha: evidence for an antioxidant sensitive activating pathway distinct from nuclear translocation". Blood 94 (6): 1878–1889. September 1999. doi:10.1182/blood.V94.6.1878.418k03_1878_1889. PMID 10477716. 
  114. ↑ "Denosumab: RANKL inhibition in the management of bone loss". Drugs of Today 44 (1): 7–21. January 2008. doi:10.1358/dot.2008.44.1.1178467. PMID 18301800. 
  115. ↑ "Targeting of nuclear factor-kappaB and proteasome by dithiocarbamate complexes with metals". Current Pharmaceutical Design 13 (30): 3155–3167. 2007. doi:10.2174/138161207782110390. PMID 17979756. 
  116. ↑ "NF-κB-activating complex engaged in response to EGFR oncogene inhibition drives tumor cell survival and residual disease in lung cancer". Cell Reports 11 (1): 98–110. April 2015. doi:10.1016/j.celrep.2015.03.012. PMID 25843712. 
  117. ↑ "Dual inhibition of canonical and noncanonical NF-κB pathways demonstrates significant antitumor activities in multiple myeloma". Clinical Cancer Research 18 (17): 4669–4681. September 2012. doi:10.1158/1078-0432.CCR-12-0779. PMID 22806876. 
  118. ↑ "Characterization of a c-Rel Inhibitor That Mediates Anticancer Properties in Hematologic Malignancies by Blocking NF-κB-Controlled Oxidative Stress Responses". Cancer Research 76 (2): 377–389. January 2016. doi:10.1158/0008-5472.CAN-14-2814. PMID 26744524. 
  119. ↑ "Inactivation of NF-kappaB components by covalent binding of (-)-dehydroxymethylepoxyquinomicin to specific cysteine residues". Journal of Medicinal Chemistry 51 (18): 5780–5788. September 2008. doi:10.1021/jm8006245. PMID 18729348. 
  120. ↑ "Role of RCP006 as an anti-inflammatory agent". Roskamp Institute. http://www.rfdn.org/inflammaging3.html. 
  121. ↑ "BAY 11-7082 ameliorates diabetic nephropathy by attenuating hyperglycemia-mediated oxidative stress and renal inflammation via NF-κB pathway". Environmental Toxicology and Pharmacology 39 (2): 690–699. March 2015. doi:10.1016/j.etap.2015.01.019. PMID 25704036. 
  122. ↑ "Suppression of NF-κB and NF-κB regulated oxidative stress and neuroinflammation by BAY 11-7082 (IκB phosphorylation inhibitor) in experimental diabetic neuropathy". Biochimie 94 (5): 1158–1165. May 2012. doi:10.1016/j.biochi.2012.01.023. PMID 22342224. 
  123. ↑ "Crosstalk between Peroxisome Proliferator-Activated Receptors and Toll-Like Receptors: A Systematic Review". Advanced Pharmaceutical Bulletin 9 (1): 12–21. February 2019. doi:10.15171/apb.2019.003. PMID 31011554. 
  124. ↑ "Iguratimod for the treatment of rheumatoid arthritis in Japan". Expert Review of Clinical Immunology 11 (5): 565–573. May 2015. doi:10.1586/1744666X.2015.1027151. PMID 25797025. 

External links



Retrieved from "https://handwiki.org/wiki/index.php?title=Biology:NF-κB&oldid=3532563"